RBX1 and plasma cell myeloma: Particularly, the over-expression of CRBN/RBX1 exemplified the potential therapeutic implication of Lenalidomide, a CRBN/RBX1 inhibitor, in severe COVID-19 patients, where CRBN/RBX1 inhibitor were reported as protective against severe COVID-19 in several myeloma patients whose standard-of-care included Lenalidomide[32].